Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LungLife AI, Inc. ( (GB:LLAI) ) has provided an announcement.
LungLife AI has announced its intention to cancel its listing on the AIM market, following unsuccessful efforts to secure a strategic partner and the viability concerns of further public market fundraising. Despite having a cash balance of $1.31 million and a runway extending into Q2 2025, the company may face an orderly winding up if no strategic agreement or funding sources are identified. The decision is prompted by a lack of binding proposals from potential partners and limited interest in additional fundraising.
More about LungLife AI, Inc.
LungLife AI is a developer of clinical diagnostic solutions focused on the early detection of lung cancer, the deadliest form of cancer worldwide. The company offers the LungLB® test, a minimally invasive blood draw technique, to provide additional information for clinicians assessing indeterminate lung nodules. LungLife AI aims to improve early detection rates of lung cancer significantly.
YTD Price Performance: 20.59%
Average Trading Volume: 101,717
Technical Sentiment Consensus Rating: Buy
See more data about LLAI stock on TipRanks’ Stock Analysis page.